Cytiva will also look to grow through expanded activity in cell and gene therapies—and additional work with customers working toward COVID-19 drugs, vaccines, and tests . . .
- Bioprocessing
- Genome Editing
- Gene Therapy
- Virology
- Coronavirus
- Drug Discovery
- Chromatography
- Tangential Flow
- Therapeutics
- Biologics
- GEN Edge
- Cell Therapy
- Danaher
- GE Healthcare
- Cell Culture
- Single-Use Systems
Cytiva Picks Up Where GE Leaves Off after $21B Deal
Danaher Pursues Expanded Activity in Cell and Gene Therapies, Additional Work with Customers Developing COVID-19 Drugs, Vaccines, and Tests.
Danaher has re-branded and re-launched the BioPharma business of GE Healthcare Life Sciences under the name Cytiva, after completing its $21.4 billion acquisition of the former GE Healthcare Life Sciences. Cytiva aims to grow its tools, tech, and services businesses, with a focus on cell and gene therapy, and a presence in the development of COVID-19 drugs, vaccines, and tests. [Cytiva]
Recently Featured
![A microfluidic device that recapitulates bone marrow and blood vessel microenvironments shows promise as a platelet bioreactor. [Italiano Laboratory]](https://www.genengnews.com/wp-content/uploads/2018/08/ItalianoLab_72214PlateletBioreactor1941002001-100x70.jpg "Bone-Marrow-on-a-Chip Churns Out Platelets")
